Browsing by Author "Gletsu-Miller, Nana"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Associations between Diet Behaviors and Measures of Glycemia, in Clinical Setting, in Obese Adolescents
    (Mary Ann Leibert, 2016-10-01) Wagner, Kelly A.; Armah, Seth M.; Smith, Lisa G.; Pike, Julie; Tu, Wanzhu; Campbell, Wayne W.; Boushey, Carol J.; Hannon, Tamara S.; Gletsu-Miller, Nana; Biostatistics, School of Public Health
    Objective: To determine the influence of dietary behaviors, assessed in a clinical setting, on measures of glycemia in overweight and obese adolescents., Study Design: The study is a retrospective, cross-sectional chart review. Eligible participants were overweight youth (N = 146, age 9–21 years) who attended the Youth Diabetes Prevention Clinic in Indianapolis, IN. Glycemic status was assessed during a 2-hour oral glucose tolerance test (OGTT). In the Bright Futures Questionnaire, a recommended clinical tool for assessing unhealthy behaviors in youth, nutrition-specific questions were modified to quantify dietary habits. Associations between dietary habits and measures of glycemia were determined using multiple linear regression models. Skewed data are presented as geometric means and 95% confidence intervals., Results: Of the 146 adolescents who were assessed [60% girls, age 13.7 years (13.3, 14.0), BMI 33.9 kg/m2 (33.3, 34.5)], 40% were diagnosed with prediabetes. Higher intake of dessert foods was associated with increased glucose levels at 2 hours following the OGTT (β = 0.23, p = 0.004), and higher intake of packaged snack foods was associated with elevated levels of hemoglobin A1c (β = 0.04, p = 0.04), independent of adiposity., Conclusions: In obese youth, high intakes of dessert and packaged snack items were associated with elevated concentrations of glucose at 2 hours following the OGTT and hemoglobin A1c. Findings demonstrate the usefulness of a modified Bright Futures Questionnaire, used in a clinical setting, for identifying dietary behaviors associated with hyperglycemia in obese adolescents., ClinicalTrials.gov registration number: NCT02535169
  • Thumbnail Image
    Item
    Comparison of Oral Iron Supplement Formulations for Normalization of Iron Status Following Roux-EN-y Gastric Bypass Surgery: a Randomized Trial
    (Springer, 2018-02) Mischler, Renee A.; Armah, Seth M.; Craig, Bruce A.; Rosen, Arthur D.; Banerjee, Ambar; Selzer, Don J.; Choi, Jennifer N.; Gletsu-Miller, Nana; Surgery, School of Medicine
    Background The evidence behind recommendations for treatment of iron deficiency (ID) following roux-en-y gastric bypass surgery (RYGB) lacks high quality studies. Setting Academic, United States Objective The objective of the study is to compare the effectiveness of oral iron supplementation using non-heme versus heme iron for treatment of iron deficiency in RYGB patients. Methods In a randomized, single-blind study, women post-RYGB and iron deficient received non-heme iron (FeSO4, 195 mg/day) or heme iron (heme-iron-polypeptide, HIP, 31.5 to 94.5 mg/day) for 8 weeks. Measures of iron status, including blood concentrations of ferritin, soluble transferrin receptor (sTfR), and hemoglobin, were assessed. Results At baseline, the mean ± standard deviation for age, BMI, and years since surgery of the sample was 41.5 ± 6.8 years, 34.4 ± 5.9 kg/m2, and 6.9 ± 3.1 years, respectively; and there were no differences between FeSO4 (N = 6) or HIP (N = 8) groups. Compliance was greater than 94%. The study was stopped early due to statistical and clinical differences between groups. Values before and after FeSO4 supplementation, expressed as least square means (95% CI) were hemoglobin, 10.8 (9.8, 11.9) to 13.0 (11.9, 14.0) g/dL; sTfR, 2111 (1556, 2864) to 1270 (934, 1737) μg/L; ferritin, 4.9 (3.4, 7.2) to 15.5 (10.6, 22.6) μg/L; and sTfR:ferritin ratio, 542 (273, 1086) to 103 (51, 204); all p < 0.0001. With HIP supplementation, no change was observed in any of the iron status biomarkers (all p > 0.05). Conclusions In accordance with recommendations, oral supplementation using FeSO4, but not HIP, was efficacious for treatment of iron deficiency after RYGB.
  • Thumbnail Image
    Item
    Dietary Intervention for Glucose Tolerance In Teens (DIG IT): Protocol of a randomized controlled trial using health coaching to prevent youth-onset type 2 diabetes
    (Elsevier, 2017-02) Wagner, Kelly A.; Braun, Ethan; Armah, Seth M.; Horan, Diarmuid; Smith, Lisa G.; Pike, Julie; Tu, Wanzhu; Hamilton, Marc T.; Delp, Edward J.; Campbell, Wayne W.; Boushey, Carol J.; Hannon, Tamara S.; Gletsu-Miller, Nana; Pediatrics, School of Medicine
    BACKGROUND: Youth-onset type 2 diabetes (T2D) is a disease that is newly emerging and behavioral strategies for its prevention are limited. Interventions that target the lifestyle behaviors of adolescents, to improve poor dietary quality and reduce excessive sedentariness, promise to reduce the risk of developing T2D. Health coaching is effective for promoting healthy behaviors in patients who have chronic disease, but few experimental studies are in adolescents. This randomized controlled trial, in adolescents with prediabetes, will determine the effectiveness of a health coaching intervention to facilitate adoption of healthy diet and activity behaviors that delay or prevent development of T2D. METHODS/DESIGN: The Dietary Intervention for Glucose Tolerance In Teens (DIG IT) trial will involve an evaluation of a health coaching intervention in adolescents with prediabetes. Eligible participants will be randomized to receive 6months of health coaching or a single dietary consultation that is standard-of-care. The primary outcome will be 2-hour oral glucose tolerance test concentration. Secondary outcomes will include measures of glycemia and insulin action as well as dietary, physical activity and sedentary behaviors measured using an electronic food record, and by inclinometer. Data will be collected before and after the intervention (at 6months) and at 12months (to assess sustainability). DISCUSSION: This trial will determine whether a health coaching intervention, a personalized and low-cost approach to modify dietary and activity behaviors, is effective and sustainable for prevention of youth-onset T2D, relative to standard-of-care. Health coaching has the potential to be widely implemented in clinical or community settings.
  • Thumbnail Image
    Item
    Recommendation on an updated standardization of serum magnesium reference ranges
    (Springer, 2022-06-10) Rosanoff, Andrea; Wes, Christina; Elin, Ronald J.; Micke, Oliver; Baniasadi, Shadi; Barbagallo, Mario; Campbell, Emily; Cheng, Fu-Chou; Costello, Rebecca B.; Gamboa-Gomez, Claudia; Guerrero-Romero, Fernando; Gletsu-Miller, Nana; von Ehrlich, Bodo; Iotti, Stefano; Kahe, Ka; Kim, Dae Jung; Kisters, Klaus; Kolisek, Martin; Kraus, Anton; Maier, Jeanette A.; Maj-Zurawska, Magdalena; Merolle, Lucia; Nechifor, Mihai; Pourdowlat, Guitti; Shechter, Michael; Song, Yiqing; Teoh, Yee Ping; Touyz, Rhian M.; Wallace, Taylor C.; Yokota, Kuninobu; Wolf, Federica; the MaGNet Global Magnesium Project (MaGNet); Epidemiology, Richard M. Fairbanks School of Public Health
    Purpose Serum magnesium is the most frequently used laboratory test for evaluating clinical magnesium status. Hypomagnesemia (low magnesium status), which is associated with many chronic diseases, is diagnosed using the serum magnesium reference range. Currently, no international consensus for a magnesemia normal range exists. Two independent groups designated 0.85 mmol/L (2.07 mg/dL; 1.7 mEq/L) as the low cut-off point defining hypomagnesemia. MaGNet discussions revealed differences in serum magnesium reference ranges used by members’ hospitals and laboratories, presenting an urgent need for standardization. Methods We gathered and compared serum magnesium reference range values from our institutions, hospitals, and colleagues worldwide. Results Serum magnesium levels designating “hypomagnesemia” differ widely. Of 43 collected values, only 2 met 0.85 mmol/L as the low cut-off point to define hypomagnesemia. The remainder had lower cut-off values, which may underestimate hypomagnesemia diagnosis in hospital, clinical, and research assessments. Current serum magnesium reference ranges stem from “normal” populations, which unknowingly include persons with chronic latent magnesium deficit (CLMD). Serum magnesium levels of patients with CLMD fall within widely used “normal” ranges, but their magnesium status is too low for long-term health. The lower serum magnesium reference (0.85 mmol/L) proposed specifically prevents the inclusion of patients with CLMD. Conclusions Widely varying serum magnesium reference ranges render our use of this important medical tool imprecise, minimizing impacts of low magnesium status or hypomagnesemia as a marker of disease risk. To appropriately diagnose, increase awareness of, and manage magnesium status, it is critical to standardize lower reference values for serum magnesium at 0.85 mmol/L (2.07 mg/dL; 1.7 mEq/L).
  • Thumbnail Image
    Item
    The magnesium global network (MaGNet) to promote research on magnesium in diseases focusing on covid-19
    (JLE, 2021) Wolf, Federica I.; Maier, Jeanette A.; Rosanoff, Andrea; Barbagallo, Mario; Baniasadi, Shadi; Castiglioni, Sara; Cheng, Fu-Chou; Colaneri Day, Sherrie; Costello, Rebecca B.; Dominguez, Ligia J.; Elin, Ronald J.; Gamboa-Gomez, Claudia; Guerrero-Romero, Fernando; Kahe, Ka; Kisters, Klaus; Kolisek, Martin; Kraus, Anton; Iotti, Stefano; Mazur, Andre; Mercado-Atri, Moises; Merolle, Lucia; Micke, Oliver; Gletsu-Miller, Nana; Nielsen, Forrest; O-Uchi, Jin; Piazza, Ornella; Plesset, Michael; Pourdowlat, Guitti; Rios, Francisco J.; Rodriguez-Moran, Martha; Scarpati, Giuliana; Shechter, Michael; Song, Yiqing; Spence, Lisa A.; Touyz, Rhian M.; Trapani, Valentina; Veronese, Nicola; von Ehrlich, Bodo; Vormann, Juergen; Wallace, Taylor C.; CMER Center for Magnesium Education, Research; Gesellschaft für Magnesium-Forschung e.V. Germany; SDRM Society (International Society for the Development of Research on Magnesium); Epidemiology, School of Public Health